Sinopharm Group Statistics

Total Valuation

Sinopharm Group has a market cap or net worth of HKD 65.07 billion. The enterprise value is 177.47 billion.

Market Cap	65.07B
Enterprise Value	177.47B

Important Dates

The next estimated earnings date is Friday, October 25, 2024.

Earnings Date	Oct 25, 2024
Ex-Dividend Date	Jun 17, 2024

Share Statistics

Sinopharm Group has 3.12 billion shares outstanding. The number of shares has decreased by -0.06% in one year.

Shares Outstanding	3.12B
Shares Change (YoY)	-0.06%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	26.68%
Float	1.34B

Valuation Ratios

The trailing PE ratio is 6.99 and the forward PE ratio is 6.45. Sinopharm Group's PEG ratio is 1.47.

PE Ratio	6.99
Forward PE	6.45
PS Ratio	0.10
PB Ratio	0.80
P/FCF Ratio	3.51
PEG Ratio	1.47

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.24, with an EV/FCF ratio of 9.58.

EV / Earnings	19.09
EV / Sales	0.28
EV / EBITDA	6.24
EV / EBIT	7.50
EV / FCF	9.58

Financial Position

The company has a current ratio of 1.35, with a Debt / Equity ratio of 0.83.

Current Ratio	1.35
Quick Ratio	1.01
Debt / Equity	0.83
Debt / EBITDA	3.99
Debt / FCF	5.86
Interest Coverage	7.89

Financial Efficiency

Return on equity (ROE) is 11.90% and return on invested capital (ROIC) is 6.04%.

Return on Equity (ROE)	11.90%
Return on Assets (ROA)	3.08%
Return on Capital (ROIC)	6.04%
Revenue Per Employee	5.58M
Profits Per Employee	81,822
Employee Count	115,959
Asset Turnover	1.39
Inventory Turnover	8.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -4.14% in the last 52 weeks. The beta is 0.88, so Sinopharm Group's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	-4.14%
50-Day Moving Average	18.80
200-Day Moving Average	20.15
Relative Strength Index (RSI)	58.18
Average Volume (20 Days)	11,713,364

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sinopharm Group had revenue of HKD 634.32 billion and earned 9.30 billion in profits. Earnings per share was 2.98.

Revenue	634.32B
Gross Profit	50.70B
Operating Income	22.42B
Pretax Income	19.60B
Net Income	9.30B
EBITDA	24.74B
EBIT	22.42B
Earnings Per Share (EPS)	2.98

Full Income Statement

Balance Sheet

The company has 46.56 billion in cash and 108.58 billion in debt, giving a net cash position of -62.02 billion or -19.88 per share.

Cash & Cash Equivalents	46.56B
Total Debt	108.58B
Net Cash	-62.02B
Net Cash Per Share	-19.88
Equity (Book Value)	131.55B
Book Value Per Share	26.01
Working Capital	106.51B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 20.96 billion and capital expenditures -2.43 billion, giving a free cash flow of 18.53 billion.

Operating Cash Flow	20.96B
Capital Expenditures	-2.43B
Free Cash Flow	18.53B
FCF Per Share	5.94

Full Cash Flow Statement

Margins

Gross margin is 7.99%, with operating and profit margins of 3.53% and 1.47%.

Gross Margin	7.99%
Operating Margin	3.53%
Pretax Margin	3.09%
Profit Margin	1.47%
EBITDA Margin	3.90%
EBIT Margin	3.53%
FCF Margin	2.92%

Dividends & Yields

This stock pays an annual dividend of 0.96, which amounts to a dividend yield of 4.59%.

Dividend Per Share	0.96
Dividend Yield	4.59%
Dividend Growth (YoY)	6.22%
Years of Dividend Growth	3
Payout Ratio	29.57%
Buyback Yield	0.06%
Shareholder Yield	4.64%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sinopharm Group has an Altman Z-Score of 2.09. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.09
Piotroski F-Score	n/a